New treatment for relapsed extensive-stage small cell lung cancer
Submitted by Anonymous (not verified) on 27 March 2026 - 12:00
New treatment for relapsed extensive-stage small cell lung cancer
Summary of opinion: Tafinlar, 26/03/2026 Positive
Submitted by Anonymous (not verified) on 27 March 2026 - 12:00
Summary of opinion: Tafinlar, 26/03/2026 Positive
Post-authorisation efficacy studies: questions and answers
Submitted by Anonymous (not verified) on 27 March 2026 - 12:00
Post-authorisation efficacy studies: questions and answers
Summary of opinion: mResvia, 26/03/2026 Positive
Submitted by Anonymous (not verified) on 27 March 2026 - 12:00
Summary of opinion: mResvia, 26/03/2026 Positive
Reflection paper on a tailored clinical approach in biosimilar development
Submitted by Anonymous (not verified) on 27 March 2026 - 12:00
Reflection paper on a tailored clinical approach in biosimilar development
Biosimilar medicines: Overview
Submitted by Anonymous (not verified) on 27 March 2026 - 12:00
Biosimilar medicines: Overview
Type-IA variations: questions and answers
Submitted by Anonymous (not verified) on 27 March 2026 - 12:00
Type-IA variations: questions and answers
Type-II variations: questions and answers
Submitted by Anonymous (not verified) on 27 March 2026 - 12:00
Type-II variations: questions and answers
Extensions of marketing authorisations: questions and answers
Submitted by Anonymous (not verified) on 27 March 2026 - 12:00
Extensions of marketing authorisations: questions and answers
Pre-authorisation guidance
Submitted by Anonymous (not verified) on 27 March 2026 - 12:00
Pre-authorisation guidance